Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028
04 août 2020 18h31 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal amount...
Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness
03 juin 2019 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., June 03, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response...
Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available
09 mai 2019 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., May 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2019 beginning at...
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
19 mars 2019 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and...
Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents
28 févr. 2019 16h45 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the...
Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results
21 févr. 2019 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018. FINANCIAL HIGHLIGHTS (in...
Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
12 févr. 2019 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19,...
Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan® (Naloxone HCI) Nasal Spray
15 oct. 2018 16h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN®...
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018
02 août 2018 16h30 HE
|
Emergent BioSolutions
Q2 2018 total revenues of $220 million, net income of $50 millionReaffirms full year 2018 financial forecast and operational goals GAITHERSBURG, Md., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Emergent...
Emergent BioSolutions Reports First Quarter 2018 Financial Results
03 mai 2018 16h30 HE
|
Emergent BioSolutions
Reaffirms full year 2018 financial forecast and operational goalsProvides Q2 2018 revenue forecast of $205M-$230M GAITHERSBURG, Md., May 03, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions...